The effect of levetiracetam on rat bone mass, structure and metabolism
Autor: | Pavel Zivny, Jana Malakova, Julius Simko, Iveta Gradosova, Helena Zivna, Sona Fekete, Vladimir Palicka |
---|---|
Rok vydání: | 2013 |
Předmět: |
Male
musculoskeletal diseases medicine.medical_specialty Levetiracetam Bone Morphogenetic Protein 2 Bone morphogenetic protein 2 Bone and Bones Collagen Type I Bone resorption N-terminal telopeptide Osteoprotegerin Bone Density Internal medicine medicine Animals Femur Rats Wistar Bone mineral business.industry ALPL Alkaline Phosphatase musculoskeletal system Piracetam Rats Endocrinology Neurology Body Composition Neurology (clinical) business Biomarkers Type I collagen |
Zdroj: | Epilepsy Research. 107:56-60 |
ISSN: | 0920-1211 |
DOI: | 10.1016/j.eplepsyres.2013.08.012 |
Popis: | Summary Objective To determine the effect of levetiracetam (LEV) Lon bone mineral density (BMD), mineral content (BMC), bone markers, body composition and bone mechanical strength in the orchidectomised (ORX) rat model. Method 16 orchidectomised Wistar rats were divided into control and test groups, 8 rats in each group. The control rats received standard laboratory diet (SLD) while rats in the test group were fed with SLD enriched with LEV for 12 weeks. BMD was measured by dual energy X-ray absorptiometry at the whole body, lumbar spine and femur. Bone marker concentrations were examined of osteoprotegerin (OPG) and insulin-like growth factor 1 (IGF-1) in serum, and amino-terminal propeptide of procollagen type I (PINP), carboxy-terminal cross-linking telopeptide of type I collagen (CTX-I), bone alkaline phosphatase (ALPL), and bone morphogenetic protein 2 (BMP-2) in bone homogenate. The femurs were used for biomechanical testing. Results Compared to the control group we found lower fat mass, lower BMD in the area of the left femur, lower BMC in both femurs, a reduced concentration of OPG, and an increased concentration of CTX-I of borderline statistical significance ( p =0.0661). Biomechanical parameters did not differ between groups. Conclusions Significant loss of BMD or BMC was seen at the left and right femur area in the LEV group. Administration of LEV in the ORX-rat model significantly decreased levels of OPG (marker of bone formation) in serum and increased levels of CTX-I (marker of bone resorption) in bone homogenate, but results in this study did not reveal any change in biomechanical bone strength. Administration of LEV in the ORX-rat model may reduce adipose tissue. Further studies in animals and humans will be needed to confirm these findings. |
Databáze: | OpenAIRE |
Externí odkaz: |